Details of Disease

General Information of Disease (ID: DISGG7K6)

Disease Name Chronic renal failure
Synonyms chronic renal failure; kidney failure, chronic; Chronic renal disease; CRF - chronic renal failure; chronic kidney failure; chronic renal failure disease
Disease Class GB61: Chronic kidney disease
Definition Impairment of the renal function due to chronic kidney damage.
Disease Hierarchy
DISW82R7: Chronic kidney disease
DIS070UC: Renal failure
DISGG7K6: Chronic renal failure
ICD Code
ICD-11
ICD-11: GB61.Z
Expand ICD-11
'GB61.Z
Disease Identifiers
MONDO ID
MONDO_0024327
MESH ID
D007676
UMLS CUI
C0022661
MedGen ID
9637
SNOMED CT ID
46177005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Diclofenac DMPIHLS Approved Small molecular drug [1]
Hydroxychloroquine DMSIVND Approved Small molecular drug [2]
Lumiracoxib DM1S4AG Approved Small molecular drug [3]
Vitamin B3 DMQVRZH Approved Small molecular drug [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
YM533 DMFEN6T Discontinued in Phase 3 Small molecular drug [5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 170 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
BDKRB2 TTGY8IW Limited Genetic Variation [6]
CRP TTWRN6M Limited Biomarker [7]
CYP2B6 TTMH124 Limited Altered Expression [8]
CYP2C19 TTZ58XG Limited Biomarker [9]
EPO TTQG4NR Limited Altered Expression [10]
GNG7 TTCMBKF Limited Genetic Variation [11]
IGF1 TTT6LOU Limited Biomarker [12]
IL31 TT1RJXK Limited Biomarker [13]
KLK4 TT4319X Limited Genetic Variation [14]
KLKB1 TTN0PCX Limited Biomarker [15]
LRP2 TTPH1AJ Limited Genetic Variation [16]
MTM1 TTY2TCU Limited Biomarker [17]
NFKB1 TTUIZKC Limited Genetic Variation [18]
NGF TTDN3LF Limited Biomarker [19]
NRG4 TTWAGKJ Limited Biomarker [20]
P2RY12 TTZ1DT0 Limited Biomarker [21]
PCSK7 TTD30LY Limited Altered Expression [22]
POR TTOQ9GZ Limited Genetic Variation [23]
PPARA TTJ584C Limited Biomarker [24]
SLCO2B1 TTDL3UZ Limited Biomarker [25]
SOST TTYRO4F Limited Biomarker [26]
TNNI3 TTNLDK6 Limited Altered Expression [27]
ADAMTS13 TTUREBK Disputed Biomarker [28]
RGMA TTURJV4 Disputed Genetic Variation [29]
ATP4A TTF1QVM moderate Genetic Variation [30]
CCR5 TTJIH8Q moderate Genetic Variation [31]
EDN1 TTJR60Z moderate Genetic Variation [32]
GFRA3 TT63XRS moderate Altered Expression [33]
GLA TTIS03D moderate Genetic Variation [34]
GNAO1 TTAXD8Z moderate Genetic Variation [35]
GSTA1 TT4P8DE moderate Genetic Variation [36]
HLA-DQB2 TTL7VOU moderate Genetic Variation [35]
KCNJ1 TTJ13ST moderate Genetic Variation [37]
KIR2DS1 TTVWAGF moderate Genetic Variation [38]
KIR2DS2 TTV3CFI moderate Biomarker [38]
KIR3DL2 TTQH3N0 moderate Biomarker [38]
LIMK2 TTASMD8 moderate Biomarker [39]
MAP2K5 TTV3O87 moderate Biomarker [40]
NEK8 TT8AH9I moderate Genetic Variation [41]
SIK1 TT1H6LC moderate Genetic Variation [29]
SLCO1B1 TTFGXEB moderate Biomarker [42]
TRPV2 TTBECWA moderate Biomarker [43]
VIPR1 TTCL30I moderate Genetic Variation [44]
VKORC1 TTEUC8H moderate Genetic Variation [45]
ABCB1 TT3OT40 Strong Genetic Variation [46]
ABCC2 TTFLHJV Strong Biomarker [47]
ABCC3 TTVLG21 Strong Biomarker [47]
ACAT1 TTK3C21 Strong Biomarker [24]
ADRA1B TTBRKXS Strong Altered Expression [48]
ADRA1D TT34BHT Strong Altered Expression [48]
AGTR2 TTQVOEI Strong Biomarker [49]
AHSG TTKF4WV Strong Altered Expression [50]
APOB TTN1IE2 Strong Biomarker [51]
ARG2 TTV1AG6 Strong Biomarker [52]
B2M TTY7FKA Strong Altered Expression [53]
BDKRB1 TTG5QIA Strong Genetic Variation [54]
BECN1 TT5M7LN Strong Biomarker [55]
BMP7 TTKOBRA Strong Biomarker [56]
CAT TTPS279 Strong Biomarker [57]
CBR1 TTVG0SN Strong Biomarker [58]
CCR1 TTC24WT Strong Biomarker [59]
CLCNKB TTR68GQ Strong Genetic Variation [60]
CLU TTRL76H Strong Biomarker [61]
CR1 TTEA8OW Strong Genetic Variation [62]
CRHR1 TT7EFHR Strong Biomarker [63]
CUBN TT9YLCR Strong Biomarker [64]
CX3CR1 TT2T98G Strong Altered Expression [65]
CYBB TT5T8MR Strong Altered Expression [66]
CYP11B2 TT9MNE2 Strong Genetic Variation [67]
CYP3A4 TTWP7HQ Strong Altered Expression [68]
DDC TTN451K Strong Biomarker [69]
DGAT1 TT0GV3R Strong Biomarker [70]
DGAT2 TTRHEQ4 Strong Biomarker [70]
DRD1 TTZFYLI Strong Therapeutic [71]
ECE1 TTQ9RYT Strong Genetic Variation [72]
EHMT1 TTOFXD7 Strong Genetic Variation [73]
ENPP1 TTZTIWS Strong Biomarker [74]
EPOR TTAUX24 Strong Biomarker [75]
F2 TT6L509 Strong Therapeutic [76]
FCAR TTGUJAO Strong Biomarker [77]
FCGR3A TTIFOC0 Strong Altered Expression [78]
FGF21 TTQ916P Strong Altered Expression [79]
GCG TT6Y4PN Strong Biomarker [80]
GIP TT40HS5 Strong Altered Expression [80]
GLP1R TTVIMDE Strong Biomarker [81]
HMGCR TTPADOQ Strong Biomarker [82]
HMOX1 TTI6V2A Strong Genetic Variation [83]
ICAM1 TTA1L39 Strong Genetic Variation [84]
IL20 TTNZMY2 Strong Biomarker [85]
INSR TTCBFJO Strong Biomarker [86]
IRS1 TTAJSQ0 Strong Biomarker [86]
KEAP1 TT3Z6Y9 Strong Biomarker [57]
KLK1 TT5T3P6 Strong Biomarker [87]
KNG1 TTDJ4MY Strong Genetic Variation [6]
LCAT TTGZ91P Strong Biomarker [88]
LHCGR TT2O4W9 Strong Biomarker [89]
LPL TTOF3WZ Strong Biomarker [90]
LTB TTHQ6US Strong Altered Expression [91]
MTOR TTCJG29 Strong Biomarker [92]
NFE2L2 TTA6ZN2 Strong Genetic Variation [93]
NOS1 TTZUFI5 Strong Therapeutic [94]
NOX4 TTQRBSJ Strong Altered Expression [95]
NQO1 TT8XK6L Strong Therapeutic [96]
NR3C1 TTOZRK6 Strong Genetic Variation [97]
NR4A1 TTMXE2Q Strong ModifyingMutation [98]
OLR1 TTKSND3 Strong Biomarker [99]
OPA1 TTTU49Q Strong Therapeutic [100]
PCSK2 TT46F0P Strong Biomarker [101]
PGF TT48I1Y Strong Biomarker [102]
PLAU TTGY7WI Strong Biomarker [103]
POSTN TT8ALTZ Strong Biomarker [104]
PRTN3 TT5MLC4 Strong Genetic Variation [105]
PTGER4 TT79WV3 Strong Therapeutic [106]
PTGS2 TTVKILB Strong Altered Expression [107]
PTH1R TTFPD47 Strong Altered Expression [108]
SCGB1A1 TTONPVW Strong Genetic Variation [109]
SERPINE1 TTTO43N Strong Therapeutic [110]
SHH TTIENCJ Strong Biomarker [111]
SLC12A3 TTP362L Strong Genetic Variation [112]
SLC17A5 TTFSUIA Strong Genetic Variation [113]
SLC19A1 TT09I7D Strong Biomarker [114]
SLC19A2 TT2A1DZ Strong Biomarker [114]
SLC19A3 TT9BTWM Strong Genetic Variation [115]
SLC22A2 TT0XOJN Strong Genetic Variation [116]
SLC33A1 TTL69WB Strong Altered Expression [117]
SLC46A1 TTY8Z2E Strong Biomarker [114]
SLC5A2 TTF8JAT Strong Biomarker [118]
SOAT2 TTAK0IN Strong Biomarker [119]
SREBF2 TTRQ4AP Strong Biomarker [24]
ST8SIA4 TTDP8YM Strong Genetic Variation [120]
TERT TTQY2EJ Strong Therapeutic [121]
TGFB1 TTR9XHZ Strong Altered Expression [122]
TRPC6 TTRBT3W Strong Biomarker [123]
UTS2 TTERU0T Strong Biomarker [124]
VCAM1 TTHCEF6 Strong Biomarker [125]
XDH TT7RJY8 Strong Therapeutic [126]
ABCA1 TTJW1GN Definitive Biomarker [24]
ABCG1 TTMWDGU Definitive Biomarker [24]
ABCG2 TTIMJ02 Definitive Genetic Variation [127]
AOC1 TTM3B5R Definitive Genetic Variation [128]
ARSA TTYQANR Definitive Biomarker [129]
ATXN2 TTPQJ7P Definitive Genetic Variation [130]
CPS1 TT42M75 Definitive Genetic Variation [116]
CRHR2 TTIY658 Definitive Altered Expression [131]
DIO1 TTU3X26 Definitive Biomarker [132]
DPEP1 TTYUENF Definitive Genetic Variation [16]
FABP1 TTIV96N Definitive Biomarker [24]
FADS2 TTT2VDU Definitive Genetic Variation [128]
FASN TT7AOUD Definitive Biomarker [24]
FTO TTFW3BT Definitive Genetic Variation [133]
GJA10 TTQMI2N Definitive Genetic Variation [127]
HBEGF TT15SL0 Definitive Biomarker [134]
IGF2R TTPNE41 Definitive Genetic Variation [128]
KCNQ1 TT846HF Definitive Genetic Variation [16]
L3MBTL3 TTQDMJN Definitive Genetic Variation [116]
MSR1 TT2TDH9 Definitive Biomarker [24]
NCF1 TTZ4JC3 Definitive Biomarker [135]
PCSK9 TTNIZ2B Definitive Biomarker [136]
PDXP TT9UYG4 Definitive Biomarker [137]
PKD2L1 TTAHD89 Definitive Genetic Variation [128]
PTGS1 TT8NGED Definitive Biomarker [135]
SCARB1 TTRE324 Definitive Biomarker [24]
SELP TTE5VG0 Definitive Biomarker [53]
SLC22A1 TTM5Q4V Definitive Genetic Variation [128]
SLC22A16 TTITAVR Definitive Genetic Variation [128]
SLC2A9 TTIF3GB Definitive Genetic Variation [16]
SLC30A8 TTXIGT7 Definitive Genetic Variation [138]
SLC47A1 TTMHCGA Definitive Genetic Variation [116]
SREBF1 TTER0UB Definitive Biomarker [24]
TFPI TT068JH Definitive Genetic Variation [139]
------------------------------------------------------------------------------------
⏷ Show the Full List of 170 DTT(s)
This Disease Is Related to 13 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC3A1 DTBCKVM Disputed Genetic Variation [140]
ATP12A DT5NLZA moderate Genetic Variation [30]
SLC24A5 DTAWCS9 moderate Genetic Variation [29]
SLC7A7 DTE4HJ8 moderate Genetic Variation [141]
SLC34A1 DT42EWA Strong Genetic Variation [116]
SLC9A6 DTN0JXW Strong Biomarker [142]
SLC9C1 DT9J8DO Strong Genetic Variation [143]
SLC13A3 DTKXTPW Definitive Genetic Variation [144]
SLC16A9 DTQK5O9 Definitive Genetic Variation [128]
SLC25A26 DT8HR5O Definitive Genetic Variation [16]
SLC4A1 DTB0Q3P Definitive Genetic Variation [145]
SLC6A13 DTX8KP0 Definitive Genetic Variation [130]
SLC7A9 DTP7AEQ Definitive Genetic Variation [128]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DTP(s)
This Disease Is Related to 11 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
APRT DE2MV1R moderate Altered Expression [146]
ABO DESIA7R Strong Biomarker [147]
ACP5 DESITDW Strong Biomarker [26]
CYP1A1 DE6OQ3W Strong Biomarker [148]
GSTM1 DEYZEJA Strong Genetic Variation [93]
GSTT1 DE3PKUG Strong Genetic Variation [149]
NAT2 DER7TA0 Strong Biomarker [150]
CHDH DEAHED0 Definitive Biomarker [151]
FADS1 DE05S8C Definitive Genetic Variation [128]
NAT8 DEA742Z Definitive Genetic Variation [130]
PRODH DEVJIHS Definitive Genetic Variation [128]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DME(s)
This Disease Is Related to 216 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ANKH OTCN25R5 Limited Altered Expression [152]
ARNT OTMSIEZY Limited Altered Expression [153]
ATF7IP OTU6ZA7F Limited Genetic Variation [154]
C1QL3 OT4TZH3J Limited Altered Expression [155]
CD68 OTOYEY3J Limited Altered Expression [156]
CEBPZ OT11BATG Limited Biomarker [157]
CFHR1 OT72R16T Limited Genetic Variation [158]
CFHR3 OTYL8SDO Limited Genetic Variation [158]
CLTC OTBFASMA Limited Genetic Variation [145]
CPD OT2CS64Y Limited Genetic Variation [10]
CPT1A OTI862QH Limited Altered Expression [159]
DIDO1 OT9PB547 Limited Biomarker [132]
DNAJB9 OT38EQT6 Limited Biomarker [160]
ENHO OT91QASK Limited Biomarker [161]
EPB41L4B OT2K30P7 Limited Biomarker [17]
ERFE OTSES1HA Limited Biomarker [162]
ESPN OT7Z6LX2 Limited Biomarker [163]
ETF1 OTH8C5U5 Limited Genetic Variation [164]
FNDC5 OT5CSK9X Limited Altered Expression [165]
GOLGA6A OTHU9MRX Limited Biomarker [166]
GRAMD2B OTGT3E98 Limited Genetic Variation [11]
GUCA2B OTZERX04 Limited Biomarker [167]
GYPA OTABU4YV Limited Biomarker [168]
KL OTD4VWU6 Limited Genetic Variation [169]
KLF15 OTGMQMVR Limited Altered Expression [170]
KTN1 OTQAV541 Limited Biomarker [17]
LYPD4 OTYNO8BS Limited Biomarker [171]
MAMLD1 OT9EVMQY Limited Biomarker [17]
MGAT4C OTQ2R629 Limited Genetic Variation [11]
MTRF1 OTRTUUM4 Limited Genetic Variation [164]
NUP42 OTADT64E Limited Biomarker [17]
OPTN OT2UXWH9 Limited Genetic Variation [172]
PRSS54 OTZVEVQZ Limited Biomarker [173]
PSMA6 OTJ6RPX5 Limited Genetic Variation [174]
PTER OTBYJHDG Limited Biomarker [175]
RBBP4 OTG3BT3M Limited Altered Expression [22]
RCBTB1 OTAYELI8 Limited Biomarker [166]
SMARCA2 OTSGJ8SV Limited Genetic Variation [176]
SMARCAL1 OTTKXLUZ Limited Biomarker [176]
SOCS2 OTBPNKJQ Limited Altered Expression [177]
TEAD1 OTK6971C Limited Biomarker [178]
TMEM245 OTR7KEXW Limited Biomarker [17]
CLDN19 OTVD6IBL Disputed Genetic Variation [179]
FRMD3 OT0CD2GG Disputed Biomarker [180]
INVS OT8KPESR Disputed Genetic Variation [181]
KIR3DL1 OTPOSXFX Disputed Biomarker [182]
MGP OTZWU3FU Disputed Altered Expression [183]
NPHP3 OT8U8ELA Disputed Genetic Variation [181]
ABCG8 OTIJ76XW moderate Genetic Variation [184]
ATP6AP2 OT0IABVV moderate Altered Expression [185]
BSND OTYWZWPD moderate Altered Expression [186]
CD151 OTF3UZS7 moderate Biomarker [187]
COL4A2 OTJK1LKN moderate Biomarker [188]
COQ8B OTBY50BD moderate Genetic Variation [189]
CORO7 OTG7MEAJ moderate Genetic Variation [190]
CPT2 OTIN6G20 moderate Altered Expression [159]
CREBRF OT2GK1HI moderate Genetic Variation [191]
DBP OTE0W7LN moderate Biomarker [192]
ELMO1 OTY2ORXK moderate Biomarker [193]
FBXO32 OTUE978R moderate Biomarker [194]
FCN1 OTK6ZHXH moderate Genetic Variation [195]
FLOT2 OTZ0QR5L moderate Biomarker [196]
FOXD3 OTXYV6GO moderate Biomarker [197]
IL17RA OTVVI8ER moderate Genetic Variation [198]
KIR3DS1 OTJWIO4T moderate Genetic Variation [38]
MCF2L OTEURA8N moderate Biomarker [199]
MCIDAS OTK1JVAH moderate Biomarker [200]
MEIS1 OTH9DKAD moderate Genetic Variation [40]
MEST OT8Q4U8Y moderate Biomarker [201]
MTFMT OT1OIVJL moderate Genetic Variation [202]
PLA2G10 OTRZ2L5A moderate Altered Expression [203]
PTX4 OTA9DN5I moderate Biomarker [204]
RFXANK OTDX1026 moderate Biomarker [205]
RNASE2 OT8Z4FNE moderate Genetic Variation [32]
RTN1 OTCX1SMK moderate Genetic Variation [206]
SCEL OT46SDNQ moderate Altered Expression [207]
SEMA6D OTU0UAZS moderate Genetic Variation [29]
SFI1 OTI1P52G moderate Biomarker [39]
SPESP1 OTWXKKTJ moderate Genetic Variation [208]
TINAG OTY7BSD7 moderate Genetic Variation [209]
TNIP1 OTRAOTEW moderate Genetic Variation [210]
TRPS1 OT7XPPEL moderate Genetic Variation [211]
ACKR2 OTWYY14H Strong Biomarker [212]
ACTN4 OTCNZAJ5 Strong Biomarker [213]
ADIPOR1 OT65ZFZN Strong Biomarker [159]
ADIPOR2 OT2HDTL8 Strong Biomarker [214]
AQP2 OTQLBKK6 Strong Genetic Variation [215]
ARID4B OTYLPILE Strong Biomarker [216]
ATP5PF OTDAE8FP Strong Biomarker [217]
BGLAP OTK1YLWQ Strong Altered Expression [218]
BNIP3 OT4SO7J4 Strong Biomarker [55]
C6 OTCKR304 Strong ModifyingMutation [219]
CABIN1 OT4G5CIK Strong Biomarker [220]
CCL14 OT8QETQU Strong Biomarker [221]
CCL15 OTOGZ85M Strong Biomarker [222]
CD2AP OTC76KQM Strong Genetic Variation [223]
CFHR5 OT7BMOYE Strong Genetic Variation [224]
CHP1 OTHTXN1A Strong Biomarker [225]
CLCN5 OT9YXZSO Strong Genetic Variation [226]
CLDN16 OTTHAIKR Strong Genetic Variation [227]
CNDP1 OTOYSQG7 Strong Biomarker [228]
COL4A4 OT9G0MCT Strong Genetic Variation [229]
COL4A5 OTHG60RE Strong Genetic Variation [230]
CYBA OT16N9ZO Strong Genetic Variation [231]
DHX16 OTW8KZAU Strong Biomarker [232]
DNAJB11 OTDDK2SY Strong Biomarker [233]
DNM1L OTXK1Q1G Strong Therapeutic [100]
EDN3 OTN7Q9BE Strong Genetic Variation [234]
ERAL1 OTSH78HD Strong Genetic Variation [235]
FCGR3B OTSLSPZG Strong Altered Expression [78]
FGB OT6RKLI9 Strong Genetic Variation [236]
FIS1 OT2HL10J Strong Therapeutic [100]
GALNT3 OT7M67WT Strong Biomarker [237]
GCKR OTSIWXGG Strong Genetic Variation [16]
GUCA2A OTUSF75G Strong Biomarker [238]
HILPDA OTEID3ZM Strong Altered Expression [239]
INF2 OT8ZM13C Strong Biomarker [240]
KIDINS220 OTLBH2MA Strong Genetic Variation [241]
KNSTRN OTYA7UXS Strong Biomarker [242]
LIPC OTZY5SC9 Strong Biomarker [243]
LPIN1 OTQ75KF2 Strong Biomarker [244]
MCTP2 OTFMZ8I2 Strong Genetic Variation [29]
MFN1 OTCBXQZF Strong Altered Expression [245]
MMP24 OTF8T3JM Strong Biomarker [246]
NPHP1 OTZHCFFQ Strong Biomarker [247]
NPHS1 OT21JD3P Strong Genetic Variation [128]
NXPH1 OTGKX860 Strong Biomarker [248]
PAPPA OTTTG9PG Strong Biomarker [249]
PKD2 OTIXBU8H Strong Genetic Variation [250]
PLCE1 OTJISZOX Strong Genetic Variation [251]
PLCL1 OTJL2C79 Strong Genetic Variation [251]
PLP1 OT8CM9CX Strong Genetic Variation [252]
POU2F3 OTIOOJWD Strong Genetic Variation [253]
PPP6R3 OTIXD60Q Strong Genetic Variation [254]
PTHLH OTI1JF13 Strong Altered Expression [255]
PTPRF OTH5KF2D Strong Genetic Variation [256]
RBM39 OTCMPTF9 Strong Biomarker [221]
RBM45 OTWTHD77 Strong Genetic Variation [257]
RELA OTUJP9CN Strong Altered Expression [258]
RETN OTW5Z1NH Strong Altered Expression [259]
RHOV OTW4N3QN Strong Biomarker [225]
RNLS OTVP2WJM Strong Genetic Variation [260]
RREB1 OT62460U Strong Genetic Variation [16]
SARNP OTE0OVK5 Strong Biomarker [221]
SDCCAG8 OTV2ZGV9 Strong Genetic Variation [261]
SHC1 OT1J5IRN Strong Altered Expression [262]
TPD52 OTPKSK43 Strong Genetic Variation [263]
TTC21B OTXXA87U Strong Genetic Variation [264]
ACADL OTP7Y0UF Definitive Genetic Variation [128]
ACADS OTGFANYQ Definitive Genetic Variation [128]
ADCY8 OTR1WCZX Definitive Genetic Variation [133]
AFF3 OTR0705Z Definitive Genetic Variation [265]
ASPG OT5E2EKR Definitive Genetic Variation [128]
BCAS3 OTDVAX6B Definitive Genetic Variation [116]
BTBD9 OTWQ6GA3 Definitive Genetic Variation [266]
C12orf75 OTFVI3EY Definitive Genetic Variation [133]
C9 OT7I5FDX Definitive Genetic Variation [116]
CALM2 OTNYA92F Definitive Genetic Variation [267]
CCSER1 OTVLD4J3 Definitive Genetic Variation [268]
CDON OT81X593 Definitive Genetic Variation [133]
CERS4 OTV5ENAX Definitive Genetic Variation [128]
CHGA OTXYX5JH Definitive Biomarker [269]
CXCL16 OTD49T9R Definitive Biomarker [270]
DAB2 OTRMQTMZ Definitive Genetic Variation [116]
DACH1 OTMKNAGG Definitive Genetic Variation [130]
DNAH17 OT4G6E70 Definitive Genetic Variation [128]
DSCAM OTL7PRMK Definitive Genetic Variation [133]
ELOVL2 OTDAF6U3 Definitive Genetic Variation [128]
EXOSC3 OTNCF906 Definitive Biomarker [53]
GATM OTIJ4Z11 Definitive Genetic Variation [116]
GRHPR OTLV63QV Definitive Genetic Variation [271]
GTPBP4 OT6ZHAWC Definitive Genetic Variation [272]
HOGA1 OT7XETW4 Definitive Genetic Variation [271]
IDI2 OTMGH91T Definitive Genetic Variation [272]
INHBC OT8SUTZR Definitive Genetic Variation [16]
KIRREL2 OTSLTR4Y Definitive Genetic Variation [128]
LARP4B OT2HI0QE Definitive Genetic Variation [116]
LMX1B OTM8145D Definitive Genetic Variation [273]
LPP OT6TU8SE Definitive Genetic Variation [16]
LRIG1 OTY5HZN5 Definitive Genetic Variation [16]
LUC7L3 OTKDED8A Definitive Genetic Variation [133]
MLXIPL OTR9MLLW Definitive Biomarker [24]
MMP20 OT16S5S3 Definitive Genetic Variation [128]
MYO19 OTWEENPY Definitive Genetic Variation [116]
MYRF OTKF6AEB Definitive Genetic Variation [128]
NFAT5 OTKIE59S Definitive Genetic Variation [16]
NFATC1 OT4TMERS Definitive Genetic Variation [116]
NFIC OTLMCUIB Definitive Genetic Variation [127]
NPHS2 OTLCNUII Definitive Genetic Variation [274]
NT5C1A OTS7UF36 Definitive Genetic Variation [275]
NTAN1 OTJF0U48 Definitive Genetic Variation [128]
PAX2 OTKP1N8F Definitive Genetic Variation [273]
PDILT OT5D60QU Definitive Genetic Variation [116]
PDXDC1 OTKH7U5Q Definitive Genetic Variation [128]
PDZRN3 OTQ891OS Definitive Genetic Variation [267]
PIP5K1B OT8JQ1F7 Definitive Genetic Variation [116]
PKD1 OT5ALRZ5 Definitive Genetic Variation [276]
PLXDC2 OTS1FUV6 Definitive Genetic Variation [277]
PRKAG2 OTHTAM54 Definitive Genetic Variation [116]
PTPRN2 OTL6SH28 Definitive Genetic Variation [128]
PTX3 OTPXHRKU Definitive Biomarker [278]
RAPGEF5 OT53VS75 Definitive Genetic Variation [279]
RGS14 OTYN79AG Definitive Genetic Variation [116]
RPN1 OTEG4KU9 Definitive Genetic Variation [133]
S100A10 OTI71243 Definitive Biomarker [53]
SFMBT1 OTKMZIBW Definitive Genetic Variation [16]
SHROOM3 OTQKC5X2 Definitive Genetic Variation [116]
SIPA1L3 OTNYFUM3 Definitive Genetic Variation [16]
SYNE2 OTBUXGQ0 Definitive Genetic Variation [128]
TFDP2 OTKQFX5H Definitive Genetic Variation [130]
THEM4 OTSIZU8Y Definitive Genetic Variation [128]
THSD7A OT7249HH Definitive Genetic Variation [133]
TLL1 OTK9NM7G Definitive Genetic Variation [277]
TMEM229B OT50LI46 Definitive Genetic Variation [128]
TMEM258 OTXSDU14 Definitive Genetic Variation [128]
TRIM49B OTVNMV6Z Definitive Genetic Variation [116]
------------------------------------------------------------------------------------
⏷ Show the Full List of 216 DOT(s)

References

1 Diclofenac FDA Label
2 Hydroxychloroquine FDA Label
3 Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32.
4 Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026064)
6 Association of the human bradykinin B2 receptor gene with chronic renal failure.Mol Diagn. 2004;8(3):157-61. doi: 10.1007/BF03260059.
7 Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis.J Nephrol. 2019 Apr;32(2):307-314. doi: 10.1007/s40620-018-0557-4. Epub 2018 Nov 21.
8 Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450.Br J Pharmacol. 2005 Apr;144(8):1067-77. doi: 10.1038/sj.bjp.0706138.
9 Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Arthritis Rheum. 2004 Jul;50(7):2202-10. doi: 10.1002/art.20338.
10 Recipient's effects on stored red blood cell performance: the case of uremic plasma.Transfusion. 2019 Jun;59(6):1900-1906. doi: 10.1111/trf.15257. Epub 2019 Mar 19.
11 Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans.Hum Genomics. 2019 May 15;13(1):21. doi: 10.1186/s40246-019-0205-7.
12 Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?.Nephrology (Carlton). 2018 Jan;23(1):31-36. doi: 10.1111/nep.12927.
13 2-Microglobulin, interleukin-31, and arachidonic acid metabolites (leukotriene B(4) and thromboxane A(2)) are involved in chronic renal failure-associated itch-associated responses in mice.Eur J Pharmacol. 2019 Mar 15;847:19-25. doi: 10.1016/j.ejphar.2019.01.017. Epub 2019 Jan 16.
14 Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.Kidney Int. 2000 Aug;58(2):730-9. doi: 10.1046/j.1523-1755.2000.00219.x.
15 Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease.Genomics. 2000 Oct 15;69(2):225-34. doi: 10.1006/geno.2000.6330.
16 Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.Mol Genet Genomics. 2018 Apr;293(2):371-379. doi: 10.1007/s00438-017-1394-1. Epub 2017 Nov 9.
17 A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity.Clin Exp Nephrol. 2019 Jan;23(1):16-25. doi: 10.1007/s10157-018-1657-0. Epub 2018 Oct 26.
18 Association of functional genetic variants of transcription factor Forkhead Box P3 and Nuclear Factor-B with end-stage renal disease and renal allograft outcome.Gene. 2016 Apr 25;581(1):57-65. doi: 10.1016/j.gene.2016.01.028. Epub 2016 Jan 19.
19 Enterochromaffin cell hyperplasia in the gut: Factors, mechanism and therapeutic clues.Life Sci. 2019 Dec 15;239:116886. doi: 10.1016/j.lfs.2019.116886. Epub 2019 Oct 31.
20 The brown fat-secreted adipokine neuregulin 4 is decreased in human and murine chronic kidney disease.Eur J Endocrinol. 2019 Aug;181(2):151-159. doi: 10.1530/EJE-19-0017.
21 Trends for and Clinical Factors Associated with Choice of Oral P2Y(12) Inhibitors for Patients on Chronic Dialysis.Cardiovasc Drugs Ther. 2019 Oct;33(5):511-521. doi: 10.1007/s10557-019-06913-w.
22 A network-based variable selection approach for identification of modules and biomarker genes associated with end-stage kidney disease.Nephrology (Carlton). 2020 Oct;25(10):775-784. doi: 10.1111/nep.13655. Epub 2019 Sep 9.
23 Evaluation of the CPR video decision aid with patients with end stage renal disease.BMC Nephrol. 2018 Sep 12;19(1):226. doi: 10.1186/s12882-018-1018-y.
24 Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.Biochim Biophys Acta. 2010 Jan;1800(1):6-15. doi: 10.1016/j.bbagen.2009.10.009. Epub 2009 Oct 28.
25 Uremic serum residue decreases SN-38 sensitivity through suppression of organic anion transporter polypeptide 2B1 in LS-180 colon cancer cells.Sci Rep. 2019 Oct 29;9(1):15464. doi: 10.1038/s41598-019-51640-9.
26 A distinct bone phenotype in ADPKD patients with end-stage renal disease.Kidney Int. 2019 Feb;95(2):412-419. doi: 10.1016/j.kint.2018.09.018.
27 Cardiac troponin-I content of skeletal muscle in patients with renal failure.Clin Biochem. 2002 Jul;35(5):421-3. doi: 10.1016/s0009-9120(02)00324-7.
28 Predictive value of ADAMTS-13 on concealed chronic renal failure in COPD patients.Int J Chron Obstruct Pulmon Dis. 2017 Dec 5;12:3495-3501. doi: 10.2147/COPD.S151983. eCollection 2017.
29 Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive Bayes classification.Diabetologia. 2014 Aug;57(8):1611-22. doi: 10.1007/s00125-014-3256-2. Epub 2014 May 29.
30 Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.Dig Dis Sci. 2017 Oct;62(10):2821-2827. doi: 10.1007/s10620-017-4725-5. Epub 2017 Aug 23.
31 Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis.Int Urol Nephrol. 2016 Jul;48(7):1163-70. doi: 10.1007/s11255-016-1293-0. Epub 2016 Apr 27.
32 Associations of genetic variants of endothelin with cardiovascular complications in patients with renal failure.BMC Nephrol. 2017 Sep 7;18(1):291. doi: 10.1186/s12882-017-0707-2.
33 Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors.J Clin Endocrinol Metab. 2012 Jan;97(1):E80-7. doi: 10.1210/jc.2011-2187. Epub 2011 Oct 26.
34 Mutation spectrum of -Galactosidase gene in Japanese patients with Fabry disease.J Hum Genet. 2019 Jul;64(7):695-699. doi: 10.1038/s10038-019-0599-z. Epub 2019 Apr 15.
35 Human leucocyte antigens: their association with end-stage renal disease in Saudi patients awaiting transplantation.Br J Biomed Sci. 2012;69(4):159-63.
36 Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients.BMC Nephrol. 2014 Jan 14;15:12. doi: 10.1186/1471-2369-15-12.
37 Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome.Nephrol Dial Transplant. 2009 May;24(5):1455-64. doi: 10.1093/ndt/gfn689. Epub 2008 Dec 18.
38 Distribution of Killer cell immunoglobulin like receptor genes in end stage renal disease among North Indian population.Hum Immunol. 2013 Oct;74(10):1339-45. doi: 10.1016/j.humimm.2013.06.015. Epub 2013 Jun 15.
39 A genome-wide association study for diabetic nephropathy genes in African Americans.Kidney Int. 2011 Mar;79(5):563-72. doi: 10.1038/ki.2010.467. Epub 2010 Dec 8.
40 MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease.J Med Genet. 2011 Jul;48(7):462-6. doi: 10.1136/jmg.2010.087858. Epub 2011 May 14.
41 Compound heterozygous mutations in NEK8 in siblings with end-stage renal disease with hepatic and cardiac anomalies.Am J Med Genet A. 2016 Mar;170(3):750-3. doi: 10.1002/ajmg.a.37512. Epub 2015 Dec 24.
42 Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.Cancer Chemother Pharmacol. 2017 Apr;79(4):783-789. doi: 10.1007/s00280-017-3276-y. Epub 2017 Mar 17.
43 Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death.Biochim Biophys Acta. 2009 Oct;1792(10):1019-26. doi: 10.1016/j.bbadis.2009.07.008. Epub 2009 Jul 18.
44 Genetic diversity of hepatitis C virus quasispecies in chronic renal failure patients in Midwest Brazil.Arch Virol. 2014 Aug;159(8):1917-25. doi: 10.1007/s00705-014-1994-6. Epub 2014 Feb 23.
45 Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.Blood Coagul Fibrinolysis. 2018 Sep;29(6):496-500. doi: 10.1097/MBC.0000000000000746.
46 Effect of MDR1 gene polymorphism on progression of end-stage renal disease.Acta Pharmacol Sin. 2007 Apr;28(4):579-83. doi: 10.1111/j.1745-7254.2007.00517.x.
47 Down-regulation of intestinal drug transporters in chronic renal failure in rats.J Pharmacol Exp Ther. 2007 Mar;320(3):978-85. doi: 10.1124/jpet.106.112631. Epub 2006 Nov 29.
48 Evidence of alpha1-adrenoceptor functional changes in omental arteries of patients with end-stage renal disease.Auton Autacoid Pharmacol. 2008 Jan;28(1):19-27. doi: 10.1111/j.1474-8673.2007.00413.x.
49 Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.J Am Soc Nephrol. 2002 Jul;13(7):1773-87. doi: 10.1097/01.asn.0000019409.17099.33.
50 Fetuin-A 742 (C/T) and 766 (C/G) polymorphic sites are associated with increased risk of myocardial infarction in older patients (?40 years of age).Mol Med Rep. 2015 Jul;12(1):1356-62. doi: 10.3892/mmr.2015.3521. Epub 2015 Mar 20.
51 A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives.Int Urol Nephrol. 2019 Jul;51(7):1173-1189. doi: 10.1007/s11255-019-02170-w. Epub 2019 May 22.
52 Effect of chronic renal failure on arginase and argininosuccinate synthetase expression.Am J Nephrol. 2006;26(3):310-8. doi: 10.1159/000094344. Epub 2006 Jun 29.
53 CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.J Clin Lab Anal. 2019 Feb;33(2):e22662. doi: 10.1002/jcla.22662. Epub 2018 Oct 15.
54 Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The End-Stage Renal Disease Study Group.J Am Soc Nephrol. 1999 Oct;10(10):2120-4. doi: 10.1681/ASN.V10102120.
55 Mitochondrial impairment in the five-sixth nephrectomy model of chronic renal failure: proteomic approach.BMC Nephrol. 2013 Oct 4;14:209. doi: 10.1186/1471-2369-14-209.
56 Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification.PLoS One. 2018 Jan 5;13(1):e0190820. doi: 10.1371/journal.pone.0190820. eCollection 2018.
57 Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.Am J Physiol Renal Physiol. 2010 Mar;298(3):F662-71. doi: 10.1152/ajprenal.00421.2009. Epub 2009 Dec 9.
58 Effect of experimental kidney disease on the functional expression of hepatic reductases.Drug Metab Dispos. 2015 Jan;43(1):100-6. doi: 10.1124/dmd.114.061150. Epub 2014 Oct 20.
59 A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.J Clin Invest. 2002 Jan;109(2):251-9. doi: 10.1172/JCI14040.
60 Chronic renal failure in a boy with classic Bartter's syndrome due to a novel mutation in CLCNKB coding for the chloride channel.Eur J Pediatr. 2009 Sep;168(9):1129-33. doi: 10.1007/s00431-008-0883-y. Epub 2008 Dec 3.
61 Urinary clusterin-a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival.Pediatr Nephrol. 2018 Jul;33(7):1189-1198. doi: 10.1007/s00467-018-3924-4. Epub 2018 Mar 6.
62 Complement receptor 1 gene polymorphism and cardiovascular disease in dialyzed end-stage renal disease patients.Hum Immunol. 2010 Sep;71(9):878-82. doi: 10.1016/j.humimm.2010.06.001. Epub 2010 Jun 9.
63 Corticotropin Releasing Factor Type 1 and 2 Receptor Signaling in the Medial Prefrontal Cortex Modulates Binge-Like Ethanol Consumption in C57BL/6J Mice.Brain Sci. 2019 Jul 19;9(7):171. doi: 10.3390/brainsci9070171.
64 Cubilin Single Nucleotide Polymorphism Variants are Associated with Macroangiopathy While a Matrix Metalloproteinase-9 Single Nucleotide Polymorphism Flip-Flop may Indicate Susceptibility of Diabetic Nephropathy in Type-2 Diabetic Patients.Nephron. 2019;141(3):156-165. doi: 10.1159/000494391. Epub 2018 Dec 17.
65 Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD).Sci Rep. 2017 Jun 8;7(1):3057. doi: 10.1038/s41598-017-03130-z.
66 Expansion of polymorphonuclear myeloid-derived suppressor cells in patients with end-stage renal disease may lead to infectious complications.Kidney Int. 2017 May;91(5):1236-1242. doi: 10.1016/j.kint.2016.12.015. Epub 2017 Feb 16.
67 Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency.J Nephrol. 2003 May-Jun;16(3):357-64.
68 CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.Br J Clin Pharmacol. 2015 Dec;80(6):1421-8. doi: 10.1111/bcp.12733. Epub 2015 Oct 3.
69 Renal dopaminergic system activity in rat remnant kidney up to twenty-six weeks after surgery.Life Sci. 2009 Mar 27;84(13-14):409-14. doi: 10.1016/j.lfs.2008.12.018. Epub 2009 Jan 8.
70 Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.Nephrol Dial Transplant. 2013 Feb;28(2):313-20. doi: 10.1093/ndt/gfs350. Epub 2012 Oct 8.
71 Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats.Hum Gene Ther. 2008 Apr;19(4):318-30. doi: 10.1089/hum.2007.138.
72 The influence of the endothelin-converting enzyme-1 gene polymorphism on the progression of autosomal dominant polycystic kidney disease.Ren Fail. 2006;28(1):21-4. doi: 10.1080/08860220500461211.
73 Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
74 Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling.Nephrol Dial Transplant. 2012 Feb;27(2):661-6. doi: 10.1093/ndt/gfr281. Epub 2011 May 19.
75 Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease.Isr Med Assoc J. 2016 Jun;18(6):326-30.
76 5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy.Am J Nephrol. 2012;35(4):356-64. doi: 10.1159/000337918. Epub 2012 Apr 2.
77 Immune complex formation in IgA nephropathy: CD89 a 'saint' or a 'sinner'?.Kidney Int. 2010 Dec;78(12):1211-3. doi: 10.1038/ki.2010.365.
78 Could there be Haemodynamic Stress Effects on Pro-Inflammatory CD14+CD16+ Monocytes during Convective-Diffusive Treatments? A Prospective Randomized Controlled Trial.Blood Purif. 2019;47(4):385-394. doi: 10.1159/000494711. Epub 2019 Jan 2.
79 Fibroblast growth factor 21 in chronic kidney disease.Clin Chim Acta. 2019 Feb;489:196-202. doi: 10.1016/j.cca.2017.11.002. Epub 2017 Nov 6.
80 Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease.J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz048. doi: 10.1210/clinem/dgz048.
81 Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.Int Urol Nephrol. 2019 Dec;51(12):2305-2313. doi: 10.1007/s11255-019-02274-3. Epub 2019 Sep 17.
82 Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin.J Hypertens. 2011 Mar;29(3):542-52. doi: 10.1097/HJH.0b013e328341cedf.
83 The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers.Pediatr Cardiol. 2015 Aug;36(6):1204-11. doi: 10.1007/s00246-015-1146-0. Epub 2015 Mar 31.
84 The intercellular adhesion molecule-1 (ICAM-1) gene polymorphism K469E in end-stage renal disease patients with cardiovascular disease.Hum Immunol. 2012 Aug;73(8):824-8. doi: 10.1016/j.humimm.2012.05.007. Epub 2012 May 15.
85 Interleukin-20 targets renal cells and is associated with chronic kidney disease.Biochem Biophys Res Commun. 2008 Sep 26;374(3):448-53. doi: 10.1016/j.bbrc.2008.07.039. Epub 2008 Jul 17.
86 Vascular insulin resistance related to endoplasmic reticulum stress in aortas from a rat model of chronic kidney disease.Am J Physiol Heart Circ Physiol. 2012 Nov 1;303(9):H1154-65. doi: 10.1152/ajpheart.00407.2012. Epub 2012 Aug 31.
87 Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.Am J Physiol Renal Physiol. 2010 Apr;298(4):F1033-40. doi: 10.1152/ajprenal.00518.2009. Epub 2010 Jan 20.
88 Lecithin-cholesterol acyltransferase (LCAT) deficiency without mutations in the coding sequence: a case report and literature review.Clin Nephrol. 2011 Oct;76(4):323-8. doi: 10.5414/cn106484.
89 Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure.Kidney Int. 1997 Mar;51(3):777-84. doi: 10.1038/ki.1997.109.
90 Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.Clin Exp Nephrol. 2012 Apr;16(2):238-43. doi: 10.1007/s10157-011-0549-3. Epub 2011 Oct 19.
91 N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity.Kidney Int. 2006 Apr;69(8):1450-4. doi: 10.1038/sj.ki.5000291.
92 Curcumin Ameliorates Chronic Renal Failure in 5/6 Nephrectomized Rats by Regulation of the mTOR/HIF-1/VEGF Signaling Pathway.Biol Pharm Bull. 2019 Jun 1;42(6):886-891. doi: 10.1248/bpb.b18-00787. Epub 2019 Mar 28.
93 Association of Nrf2, SOD2 and GPX1 Polymorphisms with Biomarkers of Oxidative Distress and Survival in End-Stage Renal Disease Patients.Toxins (Basel). 2019 Jul 23;11(7):431. doi: 10.3390/toxins11070431.
94 [Effects of shenshuai II recipe on the protein expressions of Ang II and nNOS in chronic renal failure rats' nephridial tissue].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Sep;32(9):1280-4.
95 Tubular NOX4 expression decreases in chronic kidney disease but does not modify fibrosis evolution.Redox Biol. 2019 Sep;26:101234. doi: 10.1016/j.redox.2019.101234. Epub 2019 Jun 5.
96 Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase.Free Radic Biol Med. 2012 Mar 1;52(5):880-8. doi: 10.1016/j.freeradbiomed.2011.12.007. Epub 2011 Dec 20.
97 Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor.Rheumatology (Oxford). 2019 Mar 1;58(3):447-454. doi: 10.1093/rheumatology/key319.
98 Genetic susceptibility and loss of Nr4a1 enhances macrophage-mediated renal injury in CKD.J Am Soc Nephrol. 2014 Nov;25(11):2499-510. doi: 10.1681/ASN.2013070786. Epub 2014 Apr 10.
99 LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats.Hypertens Res. 2003 Jan;26(1):117-22. doi: 10.1291/hypres.26.117.
100 Curcumin prevents mitochondrial dynamics disturbances in early 5/6 nephrectomy: Relation to oxidative stress and mitochondrial bioenergetics.Biofactors. 2017 Mar;43(2):293-310. doi: 10.1002/biof.1338. Epub 2016 Nov 1.
101 Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.Endocrinology. 2008 Feb;149(2):827-35. doi: 10.1210/en.2007-1046. Epub 2007 Nov 26.
102 Microvasculature change and placenta growth factor expression in the early stage of a rat remnant kidney model.Am J Nephrol. 2006;26(1):97-104. doi: 10.1159/000092032. Epub 2006 Mar 14.
103 Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.Nephrol Dial Transplant. 2020 Mar 1;35(3):465-470. doi: 10.1093/ndt/gfy265.
104 Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells.Nephrol Dial Transplant. 2012 Jul;27(7):2702-11. doi: 10.1093/ndt/gfr670. Epub 2011 Dec 13.
105 Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjgren's syndrome?.Rheumatol Int. 2020 Jul;40(7):1063-1070. doi: 10.1007/s00296-019-04476-5. Epub 2019 Nov 12.
106 Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure.Kidney Int. 2006 Sep;70(6):1099-106. doi: 10.1038/sj.ki.5001715. Epub 2006 Jul 26.
107 Prostaglandin E2 receptor EP2 mediates the effect of cyclooxygenase 2 on secondary parathyroid hyperplasia in end-stage renal disease.Nephrol Dial Transplant. 2019 Apr 1;34(4):606-617. doi: 10.1093/ndt/gfy194.
108 Role of parathyroid hormone-related peptide and Indian hedgehog in skeletal development.Pediatr Nephrol. 2000 Jul;14(7):606-11. doi: 10.1007/s004670000343.
109 Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients.Kidney Int. 2002 May;61(5):1853-8. doi: 10.1046/j.1523-1755.2002.00336.x.
110 An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure.Sci Rep. 2016 Feb 23;6:22151. doi: 10.1038/srep22151.
111 Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury.J Am Soc Nephrol. 2014 Oct;25(10):2187-200. doi: 10.1681/ASN.2013080893. Epub 2014 Apr 17.
112 Arg913Gln variation of SLC12A3 gene is associated with diabetic nephropathy in type 2 diabetes and Gitelman syndrome: a systematic review.BMC Nephrol. 2019 Oct 28;20(1):393. doi: 10.1186/s12882-019-1590-9.
113 The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients.Saudi J Gastroenterol. 2018 Jan-Feb;24(1):25-29. doi: 10.4103/sjg.SJG_100_17.
114 Effect of chronic kidney disease on the expression of thiamin and folic acid transporters.Nephrol Dial Transplant. 2011 Jul;26(7):2137-44. doi: 10.1093/ndt/gfq675. Epub 2010 Dec 13.
115 Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.Diabetes. 2016 Apr;65(4):1022-30. doi: 10.2337/db15-1247. Epub 2015 Dec 30.
116 A catalog of genetic loci associated with kidney function from analyses of a million individuals.Nat Genet. 2019 Jun;51(6):957-972. doi: 10.1038/s41588-019-0407-x. Epub 2019 May 31.
117 Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus.J Am Soc Nephrol. 1999 Mar;10(3):545-51. doi: 10.1681/ASN.V103545.
118 Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11.
119 Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E676-81. doi: 10.1152/ajpendo.00364.2001.
120 Human SA gene Pst1 polymorphism and chronic renal failure: results of the family-based study.Nephrol Dial Transplant. 2001 Feb;16(2):387-90. doi: 10.1093/ndt/16.2.387.
121 Angiogenic effect of endothelial progenitor cells transfected with telomerase reverse transcriptase on peritubular microvessel in five out of six subtotal nephrectomy rats.Ren Fail. 2012;34(10):1270-80. doi: 10.3109/0886022X.2012.723592. Epub 2012 Sep 26.
122 Decreased expression of transforming growth factor-1 and -smooth muscle actin contributes to the protection of lotensin against chronic renal failure in rats.Ren Fail. 2018 Nov;40(1):583-589. doi: 10.1080/0886022X.2018.1496934.
123 Renal Fibrosis, Immune Cell Infiltration and Changes of TRPC Channel Expression after Unilateral Ureteral Obstruction in Trpc6-/- Mice.Cell Physiol Biochem. 2019;52(6):1484-1502. doi: 10.33594/000000103.
124 Urotensin II: a cardiovascular and renal update.Curr Opin Nephrol Hypertens. 2008 Mar;17(2):199-204. doi: 10.1097/MNH.0b013e3282f49566.
125 High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease.Clin Exp Nephrol. 2010 Dec;14(6):536-47. doi: 10.1007/s10157-010-0340-x. Epub 2010 Sep 7.
126 Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages.Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F339-49. doi: 10.1152/ajprenal.00158.2012. Epub 2012 May 23.
127 Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease.Sci Rep. 2018 Sep 4;8(1):13184. doi: 10.1038/s41598-018-31282-z.
128 Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.J Am Soc Nephrol. 2018 May;29(5):1513-1524. doi: 10.1681/ASN.2017101099. Epub 2018 Mar 15.
129 Arylsulphatase A Pseudodeficiency (ARSA-PD), hypertension and chronic renal disease in Aboriginal Australians.Sci Rep. 2018 Jul 19;8(1):10912. doi: 10.1038/s41598-018-29279-9.
130 New loci associated with kidney function and chronic kidney disease.Nat Genet. 2010 May;42(5):376-84. doi: 10.1038/ng.568. Epub 2010 Apr 11.
131 Hypothalamic mechanisms associated with corticotropin-releasing factor-induced anorexia in chicks.Neuropeptides. 2019 Apr;74:95-102. doi: 10.1016/j.npep.2019.01.003. Epub 2019 Jan 11.
132 The relationship between inflammatory factors, oxidative stress and DIO-1 concentration in patients with chronic renal failure accompanied with or without euthyroid sick syndrome.J Int Med Res. 2018 Oct;46(10):4061-4070. doi: 10.1177/0300060518778190. Epub 2018 Aug 28.
133 Genetics of Chronic Kidney Disease Stages Across Ancestries: The PAGE Study.Front Genet. 2019 May 24;10:494. doi: 10.3389/fgene.2019.00494. eCollection 2019.
134 Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease.Kidney Int. 2012 Jan;81(1):40-55. doi: 10.1038/ki.2011.306. Epub 2011 Sep 21.
135 Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.Am J Physiol Renal Physiol. 2009 Jul;297(1):F106-13. doi: 10.1152/ajprenal.00126.2009. Epub 2009 May 6.
136 Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis.Eur J Clin Invest. 2019 Jul;49(7):e13113. doi: 10.1111/eci.13113. Epub 2019 Apr 8.
137 Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention.Heart. 2018 May;104(9):767-772. doi: 10.1136/heartjnl-2017-311975. Epub 2017 Nov 1.
138 A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.Diabetes. 2018 Jul;67(7):1414-1427. doi: 10.2337/db17-0914. Epub 2018 Apr 27.
139 The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor.Ann Transl Med. 2019 Aug;7(16):391. doi: 10.21037/atm.2019.07.57.
140 Renin-angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients.Ren Fail. 2009;31(3):196-200. doi: 10.1080/08860220802669826.
141 Molecular and clinical evaluation of Turkish patients with lysinuric protein intolerance.Gene. 2013 Jun 1;521(2):293-5. doi: 10.1016/j.gene.2013.03.033. Epub 2013 Mar 28.
142 Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease.Infect Control Hosp Epidemiol. 2006 Oct;27(10):1057-62. doi: 10.1086/507958. Epub 2006 Sep 18.
143 Human Na+/H+ exchanger genes : identification of polymorphisms by radiation hybrid mapping and analysis of linkage in end-stage renal disease.Hypertension. 2000 Jan;35(1 Pt 1):135-43. doi: 10.1161/01.hyp.35.1.135.
144 An integrative study of the genetic, social and environmental determinants of chronic kidney disease characterized by tubulointerstitial damages in the North Central Region of Sri Lanka.J Occup Health. 2014;56(1):28-38. doi: 10.1539/joh.13-0172-oa. Epub 2013 Dec 18.
145 Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):82-87. doi: 10.1016/j.clinre.2018.08.003. Epub 2018 Aug 27.
146 Apparent Correlations Between AMPK Expression and Brain Inflammatory Response and Neurological Function Factors in Rats with Chronic Renal Failure.J Mol Neurosci. 2019 Jun;68(2):204-213. doi: 10.1007/s12031-019-01299-8. Epub 2019 Mar 27.
147 Clinical Outcomes of ABO-Incompatible Kidney Transplantation in Patients with End-Stage Kidney Disease due to Diabetes Nephropathy.Urol Int. 2019;102(3):341-347. doi: 10.1159/000496029. Epub 2019 Jan 10.
148 Downregulation of intestinal cytochrome p450 in chronic renal failure.J Am Soc Nephrol. 2002 Jun;13(6):1579-85. doi: 10.1097/01.asn.0000017575.50319.77.
149 Association between GSTM1, GSTT1, and GSTP1 variants and the risk of end stage renal disease.Ren Fail. 2016 Oct;38(9):1455-1461. doi: 10.1080/0886022X.2016.1214054. Epub 2016 Aug 8.
150 Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.Drug Metab Dispos. 2010 Mar;38(3):357-60. doi: 10.1124/dmd.109.029991. Epub 2009 Dec 9.
151 Does dietary nitrate say NO to cardiovascular ageing? Current evidence and implications for research.Proc Nutr Soc. 2018 May;77(2):112-123. doi: 10.1017/S0029665118000058.
152 Wnt1 inhibits vascular smooth muscle cell calcification by promoting ANKH expression.J Mol Cell Cardiol. 2019 Oct;135:10-21. doi: 10.1016/j.yjmcc.2019.07.008. Epub 2019 Jul 27.
153 Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure.J Clin Invest. 2018 Jul 2;128(7):3053-3070. doi: 10.1172/JCI89632. Epub 2018 Jun 11.
154 Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial.Nutr Metab (Lond). 2019 Mar 12;16:18. doi: 10.1186/s12986-019-0343-x. eCollection 2019.
155 CTRP13 attenuates vascular calcification by regulating Runx2.FASEB J. 2019 Aug;33(8):9627-9637. doi: 10.1096/fj.201900293RRR. Epub 2019 May 30.
156 Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease.Nutrition. 2009 Jul-Aug;25(7-8):762-8. doi: 10.1016/j.nut.2008.12.012.
157 Decreased cerebral blood flow and improved cognitive function in patients with end-stage renal disease after peritoneal dialysis: An arterial spin-labelling study.Eur Radiol. 2019 Mar;29(3):1415-1424. doi: 10.1007/s00330-018-5675-9. Epub 2018 Aug 13.
158 The autoimmune disease DEAP-hemolytic uremic syndrome.Semin Thromb Hemost. 2010 Sep;36(6):625-32. doi: 10.1055/s-0030-1262884. Epub 2010 Sep 23.
159 Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.Nephrol Dial Transplant. 2014 Dec;29(12):2268-77. doi: 10.1093/ndt/gfu249. Epub 2014 Jul 21.
160 Heavy Chain Fibrillary Glomerulonephritis: A Case Report.Am J Kidney Dis. 2019 Aug;74(2):276-280. doi: 10.1053/j.ajkd.2019.01.032. Epub 2019 Apr 5.
161 Adropin and irisin: New biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study.Adv Clin Exp Med. 2019 Mar;28(3):347-353. doi: 10.17219/acem/81538.
162 Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study.J Clin Med. 2019 Apr 16;8(4):523. doi: 10.3390/jcm8040523.
163 Vascular access in children requiring maintenance haemodialysis: a consensus document by the European Society for Paediatric Nephrology Dialysis Working Group.Nephrol Dial Transplant. 2019 Oct 1;34(10):1746-1765. doi: 10.1093/ndt/gfz011.
164 Linkage heterogeneity of end-stage renal disease on human chromosome 10.Kidney Int. 2002 Sep;62(3):770-4. doi: 10.1046/j.1523-1755.2002.00534.x.
165 Urotensin II Induces Mice Skeletal Muscle Atrophy Associated with Enhanced Autophagy and Inhibited Irisin Precursor (Fibronectin Type III Domain Containing 5) Expression in Chronic Renal Failure.Kidney Blood Press Res. 2019;44(4):479-495. doi: 10.1159/000499880. Epub 2019 Jun 25.
166 Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.Diabetes Metab. 2019 Apr;45(2):110-121. doi: 10.1016/j.diabet.2018.10.003. Epub 2018 Oct 25.
167 Guanylin and uroguanylin regulate electrolyte transport in isolated human cortical collecting ducts.Kidney Int. 2005 Apr;67(4):1420-7. doi: 10.1111/j.1523-1755.2005.00219.x.
168 Improving Mortality in End-Stage Renal Disease Due to Granulomatosis With Polyangiitis (Wegener's) From 1995 to 2014: Data From the United States Renal Data System.Arthritis Care Res (Hoboken). 2018 Oct;70(10):1495-1500. doi: 10.1002/acr.23521. Epub 2018 Sep 1.
169 Association of klotho gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease.Nephrology (Carlton). 2019 Oct;24(10):1001-1008. doi: 10.1111/nep.13547. Epub 2019 May 2.
170 Loss of KLF15 accelerates chronic podocyte injury.Int J Mol Med. 2018 Sep;42(3):1593-1602. doi: 10.3892/ijmm.2018.3726. Epub 2018 Jun 11.
171 Danshen can interact with intestinal bacteria from normal and chronic renal failure rats.Biomed Pharmacother. 2019 Jan;109:1758-1771. doi: 10.1016/j.biopha.2018.11.047. Epub 2018 Nov 26.
172 Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.Transpl Int. 2018 Feb;31(2):175-186. doi: 10.1111/tri.13075. Epub 2017 Oct 12.
173 Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes.Metabolism. 2016 Feb;65(2):12-9. doi: 10.1016/j.metabol.2015.10.004. Epub 2015 Oct 28.
174 Association between functional variant of inflammatory system gene (PSMA6) and end-stage kidney disease.Int Urol Nephrol. 2016 Dec;48(12):2083-2087. doi: 10.1007/s11255-016-1420-y. Epub 2016 Sep 26.
175 Phosphotriesterase-related protein sensed albuminuria and conferred renal tubular cell activation in membranous nephropathy.J Biomed Sci. 2014 Apr 22;21(1):32. doi: 10.1186/1423-0127-21-32.
176 Insights into the renal pathogenesis in Schimke immuno-osseous dysplasia: A renal histological characterization and expression analysis.J Histochem Cytochem. 2015 Jan;63(1):32-44. doi: 10.1369/0022155414558335. Epub 2014 Oct 15.
177 Indoxyl sulfate-induced TNF- is regulated by crosstalk between the aryl hydrocarbon receptor, NF-B, and SOCS2 in human macrophages.FASEB J. 2019 Oct;33(10):10844-10858. doi: 10.1096/fj.201900730R. Epub 2019 Jul 5.
178 Economic Issues of Chronic Kidney Disease and End-Stage Renal Disease.Contrib Nephrol. 2019;198:87-93. doi: 10.1159/000496533. Epub 2019 Apr 16.
179 Claudin-19 mutations and clinical phenotype in Spanish patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.PLoS One. 2013;8(1):e53151. doi: 10.1371/journal.pone.0053151. Epub 2013 Jan 3.
180 Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease.PLoS One. 2014 Feb 13;9(2):e88273. doi: 10.1371/journal.pone.0088273. eCollection 2014.
181 Mutations of NPHP2 and NPHP3 in infantile nephronophthisis.Kidney Int. 2009 Apr;75(8):839-47. doi: 10.1038/ki.2008.662. Epub 2009 Jan 28.
182 Putative role of KIR3DL1/3DS1 alleles and HLA-Bw4 ligands with end stage renal disease and long term renal allograft survival.Gene. 2017 Dec 30;637:219-229. doi: 10.1016/j.gene.2017.09.033. Epub 2017 Sep 21.
183 Renal matrix Gla protein expression increases progressively with CKD and predicts renal outcome.Exp Mol Pathol. 2018 Aug;105(1):120-129. doi: 10.1016/j.yexmp.2018.07.001. Epub 2018 Jul 6.
184 ABCG8 polymorphisms and renal disease in type 2 diabetic patients.Metabolism. 2015 Jun;64(6):713-9. doi: 10.1016/j.metabol.2015.03.005. Epub 2015 Mar 14.
185 Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy.Peptides. 2010 Jul;31(7):1405-8. doi: 10.1016/j.peptides.2010.04.003. Epub 2010 Apr 10.
186 Renal dysfunction and barttin expression in Bartter syndrome Type IV associated with a G47R mutation in BSND in a family.Clin Nephrol. 2011 Feb;75 Suppl 1:69-74.
187 Blood pressure influences end-stage renal disease of Cd151 knockout mice.J Clin Invest. 2012 Jan;122(1):348-58. doi: 10.1172/JCI58878. Epub 2011 Dec 27.
188 Evaluation of non-response to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey.BMC Health Serv Res. 2018 Oct 19;18(1):790. doi: 10.1186/s12913-018-3618-4.
189 Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment.Pediatr Nephrol. 2017 Aug;32(8):1369-1375. doi: 10.1007/s00467-017-3634-3. Epub 2017 Mar 24.
190 Hepatic ischemia/reperfusion injury associates with acute kidney injury in liver transplantation: Prospective cohort study.Liver Transpl. 2017 May;23(5):634-644. doi: 10.1002/lt.24728.
191 Association of CREBRF variants with obesity and diabetes in Pacific Islanders from Guam and Saipan.Diabetologia. 2019 Sep;62(9):1647-1652. doi: 10.1007/s00125-019-4932-z. Epub 2019 Jul 6.
192 Changes in whole blood viscosity during hemodialysis and mortality in patients with end-stage renal disease.Clin Hemorheol Microcirc. 2017;65(3):285-297. doi: 10.3233/CH-16183.
193 High Elmo1 expression aggravates and low Elmo1 expression prevents diabetic nephropathy.Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2218-22. doi: 10.1073/pnas.1600511113. Epub 2016 Feb 8.
194 Astragalus polysaccharide, a component of traditional Chinese medicine, inhibits muscle cell atrophy (cachexia) in an in vivo and in vitro rat model of chronic renal failure by activating the ubiquitin-proteasome pathway.Exp Ther Med. 2017 Jul;14(1):91-96. doi: 10.3892/etm.2017.4492. Epub 2017 May 22.
195 Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus.Clin Rheumatol. 2017 Feb;36(2):335-341. doi: 10.1007/s10067-016-3508-2. Epub 2016 Dec 15.
196 Personalized Anemia Management and Precision Medicine in ESA and Iron Pharmacology in End-Stage Kidney Disease.Semin Nephrol. 2018 Jul;38(4):410-417. doi: 10.1016/j.semnephrol.2018.05.010.
197 Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.Free Radic Biol Med. 2015 Sep;86:16-24. doi: 10.1016/j.freeradbiomed.2015.04.002. Epub 2015 Apr 8.
198 Gene polymorphisms of interleukin-17 and interleukin-17 receptor are associated with end-stage kidney disease.Am J Nephrol. 2012;36(5):472-7. doi: 10.1159/000343571. Epub 2012 Nov 7.
199 Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.Gene. 2013 Sep 15;527(1):42-7. doi: 10.1016/j.gene.2013.05.050. Epub 2013 Jun 10.
200 Analysis of mandibular changes using panoramic-based indices in patients with chronic renal failure.Int J Artif Organs. 2017 Sep 29:0. doi: 10.5301/ijao.5000649. Online ahead of print.
201 A validation study of crescents in predicting ESRD in patients with IgA nephropathy.J Transl Med. 2018 May 3;16(1):115. doi: 10.1186/s12967-018-1488-5.
202 Challenges managing end-stage renal disease and kidney transplantation in a child with MTFMT mutation and moyamoya disease.Pediatr Transplant. 2016 Nov;20(7):1000-1003. doi: 10.1111/petr.12758. Epub 2016 Jul 8.
203 Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.J Mol Med (Berl). 2010 Jan;88(1):75-83. doi: 10.1007/s00109-009-0543-3. Epub 2009 Oct 2.
204 Therapeutic experience of severe and recurrent secondary hyperparathyroidism in a patient on hemodialysis for 18 years: A case report.Medicine (Baltimore). 2018 May;97(20):e10816. doi: 10.1097/MD.0000000000010816.
205 Comparison of multiple fluid status assessment methods in patients on chronic hemodialysis.Int Urol Nephrol. 2017 Mar;49(3):525-532. doi: 10.1007/s11255-016-1473-y. Epub 2016 Dec 10.
206 Association Analysis of the Reticulon 1 Gene in End-Stage Kidney Disease.Am J Nephrol. 2015;42(4):259-64. doi: 10.1159/000441199. Epub 2015 Oct 24.
207 High risk of development of renal cell tumor in end-stage kidney disease: the role of microenvironment.Tumour Biol. 2016 Jul;37(7):9511-9. doi: 10.1007/s13277-016-4855-y. Epub 2016 Jan 20.
208 Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans.Hum Genet. 2014 Jun;133(6):769-779. doi: 10.1007/s00439-013-1415-z. Epub 2014 Jan 3.
209 A tubulointerstitial nephritis antigen gene defect causes childhood-onset chronic renal failure.Pediatr Nephrol. 2010 Jul;25(7):1349-53. doi: 10.1007/s00467-010-1463-8. Epub 2010 Feb 16.
210 Association of Tumor Necrosis Factor Alpha-Induced Protein 3 Interacting Protein 1 (TNIP1) Gene Polymorphism (rs7708392) with Lupus Nephritis in Egyptian Patients.Biochem Genet. 2018 Oct;56(5):478-488. doi: 10.1007/s10528-018-9855-8. Epub 2018 Mar 27.
211 Tricho-rhino-phalangeal syndrome in a 13-year-old girl with chronic renal failure and severe growth retardation.Ren Fail. 2014 May;36(4):619-22. doi: 10.3109/0886022X.2014.882237. Epub 2014 Feb 6.
212 The Atypical Chemokine Receptor 2 Limits Progressive Fibrosis after Acute Ischemic Kidney Injury.Am J Pathol. 2019 Feb;189(2):231-247. doi: 10.1016/j.ajpath.2018.09.016. Epub 2018 Nov 16.
213 Functional Validation of an Alpha-Actinin-4 Mutation as a Potential Cause of an Aggressive Presentation of Adolescent Focal Segmental Glomerulosclerosis: Implications for Genetic Testing.PLoS One. 2016 Dec 15;11(12):e0167467. doi: 10.1371/journal.pone.0167467. eCollection 2016.
214 Changes of adiponectin and its receptors in rats following chronic renal failure.Ren Fail. 2014 Feb;36(1):92-7. doi: 10.3109/0886022X.2013.830975. Epub 2013 Sep 13.
215 Study of the association of -667 aquaporin-2 (AQP-2) A/G promoter polymorphism with the incidence and clinical course of chronic kidney disease in Korea.Ren Fail. 2007;29(6):693-8. doi: 10.1080/08860220701460079.
216 Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements.Nutr Metab (Lond). 2018 May 3;15:33. doi: 10.1186/s12986-018-0271-1. eCollection 2018.
217 Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.Kidney Int. 2003 Dec;64(6):2291-7. doi: 10.1046/j.1523-1755.2003.00334.x.
218 Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients.Curr Vasc Pharmacol. 2018;16(6):603-609. doi: 10.2174/1570161115666170919182421.
219 C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys.J Am Soc Nephrol. 2002 Apr;13(4):928-936. doi: 10.1681/ASN.V134928.
220 Peritoneal Dialysis in Orthotopic Liver Transplantation Recipients.Perit Dial Int. 2018 Jan-Feb;38(1):44-48. doi: 10.3747/pdi.2017.00134. Epub 2017 Nov 21.
221 HCC-1, a novel chemokine from human plasma.J Exp Med. 1996 Jan 1;183(1):295-9. doi: 10.1084/jem.183.1.295.
222 Increase of expression and activation of chemokine CCL15 in chronic renal failure.Biochem Biophys Res Commun. 2006 Jul 14;345(4):1504-12. doi: 10.1016/j.bbrc.2006.05.057. Epub 2006 May 17.
223 Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice.Kidney Int. 2019 Jan;95(1):57-61. doi: 10.1016/j.kint.2018.08.014. Epub 2018 Oct 26.
224 A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy.PLoS One. 2012;7(2):e31021. doi: 10.1371/journal.pone.0031021. Epub 2012 Feb 2.
225 Autosomal dominant progressive nephropathy with deafness: linkage to a new locus on chromosome 11q24.J Am Soc Nephrol. 2003 Jul;14(7):1794-803. doi: 10.1097/01.asn.0000071513.73427.97.
226 Dent's disease and prevalence of renal stones in dialysis patients in Northeastern Italy.J Hum Genet. 2006;51(1):25-30. doi: 10.1007/s10038-005-0317-x. Epub 2005 Oct 25.
227 Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene.Pediatr Nephrol. 2002 Aug;17(8):602-8. doi: 10.1007/s00467-002-0884-4. Epub 2002 Jun 11.
228 Monoclonal Antibody RYSK173 Recognizes the Dinuclear Zn Center of Serum Carnosinase 1 (CN-1): Possible Consequences of Zn Binding for CN-1 Recognition by RYSK173.PLoS One. 2016 Jan 22;11(1):e0146831. doi: 10.1371/journal.pone.0146831. eCollection 2016.
229 Possible Digenic Disease in a Caucasian Family with COL4A3 and COL4A5 Mutations.Nephron. 2019;141(3):213-218. doi: 10.1159/000495764. Epub 2019 Jan 18.
230 Lessons learned from a multidisciplinary renal genetics clinic.QJM. 2017 Jul 1;110(7):453-457. doi: 10.1093/qjmed/hcx030.
231 RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up.Acta Diabetol. 2016 Jun;53(3):469-75. doi: 10.1007/s00592-015-0820-2. Epub 2015 Nov 25.
232 Vitamin D binding protein and the need for vitamin D in hemodialysis patients.J Ren Nutr. 2008 Sep;18(5):400-7. doi: 10.1053/j.jrn.2008.04.013.
233 Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.
234 Association of endothelin genetic variants and hospitalized infection complications in end-stage renal disease (ESRD) patients.BMC Nephrol. 2019 Jun 5;20(1):203. doi: 10.1186/s12882-019-1349-3.
235 The European Renal Association?European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary.Clin Kidney J. 2019 Feb 26;12(5):702-720. doi: 10.1093/ckj/sfz011. eCollection 2019 Oct.
236 Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.Pharmacogenet Genomics. 2009 Jun;19(6):415-21. doi: 10.1097/FPC.0b013e32832a8e81.
237 Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.Biochim Biophys Acta. 2009 Sep;1792(9):847-52. doi: 10.1016/j.bbadis.2008.10.008. Epub 2008 Oct 25.
238 Structural impact analysis of missense SNPs present in the uroguanylin gene by long-term molecular dynamics simulations.J Theor Biol. 2016 Dec 7;410:9-17. doi: 10.1016/j.jtbi.2016.09.008. Epub 2016 Sep 9.
239 Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.J Urol. 2008 Aug;180(2):481-5. doi: 10.1016/j.juro.2008.04.006. Epub 2008 Jun 11.
240 Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic.BMC Med Genet. 2018 Aug 20;19(1):147. doi: 10.1186/s12881-018-0667-9.
241 Is low-frequency distribution of TGF-beta genotype associated with increased risk for end-stage renal disease?.DNA Cell Biol. 2007 Mar;26(3):172-7. doi: 10.1089/dna.2006.0520.
242 The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.J Hypertens. 2000 Mar;18(3):241-8. doi: 10.1097/00004872-200018030-00001.
243 Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone.J Clin Invest. 1996 May 15;97(10):2167-73. doi: 10.1172/JCI118657.
244 Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.FASEB J. 2004 Jan;18(1):39-51. doi: 10.1096/fj.03-0610com.
245 Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease.Nephrology (Carlton). 2020 Mar;25(3):230-238. doi: 10.1111/nep.13606. Epub 2019 Jun 7.
246 Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients.Am J Physiol Renal Physiol. 2001 Aug;281(2):F309-17. doi: 10.1152/ajprenal.2001.281.2.F309.
247 Two novel homozygous mutations in NPHP1 lead to late onset end-stage renal disease: a case report of an adult nephronophthisis in a Chinese intermarriage family.BMC Nephrol. 2019 May 16;20(1):173. doi: 10.1186/s12882-019-1372-4.
248 Molecular genetic identification of families with juvenile nephronophthisis type 1: rate of progression to renal failure. APN Study Group. Arbeitsgemeinschaft fr Pdiatrische Nephrologie.Kidney Int. 1997 Jan;51(1):261-9. doi: 10.1038/ki.1997.31.
249 Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation.Nephrol Dial Transplant. 2018 Jun 1;33(6):971-977. doi: 10.1093/ndt/gfx215.
250 Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148.
251 Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006 Dec;38(12):1397-405. doi: 10.1038/ng1918. Epub 2006 Nov 5.
252 Homocysteine, B vitamins, and vascular-access thrombosis in patients treated with hemodialysis.Am J Kidney Dis. 1998 Sep;32(3):475-81. doi: 10.1053/ajkd.1998.v32.pm9740165.
253 Platelet GP IIIA polymorphism HPA-1 (PLA1/2) is associated with hypertension as the primary cause for end-stage renal disease in hemodialysis patients from Greece.In Vivo. 2009 Jan-Feb;23(1):177-81.
254 Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgery?"Schrutka L. Binder C
255 Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2.Kidney Int. 2013 May;83(5):825-34. doi: 10.1038/ki.2012.476. Epub 2013 Jan 30.
256 Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.
257 A single center study of protective and susceptible HLA alleles and haplotypes with end-stage renal disease in China.Hum Immunol. 2019 Nov;80(11):943-947. doi: 10.1016/j.humimm.2019.09.001. Epub 2019 Sep 11.
258 NF-B plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells.Am J Physiol Cell Physiol. 2011 Nov;301(5):C1201-12. doi: 10.1152/ajpcell.00471.2010. Epub 2011 Aug 10.
259 Serum Resistin, Adenylate Cyclase-Associated Protein 1 Gene Expression, and Carotid Intima-Media Thickness in Patients with End-Stage Renal Disease and Healthy Controls.Cardiorenal Med. 2020;10(1):51-60. doi: 10.1159/000503416. Epub 2019 Nov 13.
260 Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension.Nephrol Dial Transplant. 2012 Nov;27(11):4162-6. doi: 10.1093/ndt/gfr293. Epub 2011 May 26.
261 Rapidly Progressive Nephronophthisis in a 2-Year-Old Boy with a Homozygous SDCCAG8 Mutation.Tohoku J Exp Med. 2019 Sep;249(1):29-32. doi: 10.1620/tjem.249.29.
262 Decreased p66Shc promoter methylation in patients with end-stage renal disease.Clin Chem Lab Med. 2007;45(12):1764-70. doi: 10.1515/CCLM.2007.357.
263 Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR.Clin Chem Lab Med. 2006;44(12):1410-5. doi: 10.1515/CCLM.2006.252.
264 Mutations in TTC21B cause different phenotypes in two childhood cases in China.Nephrology (Carlton). 2018 Apr;23(4):371-376. doi: 10.1111/nep.13008.
265 The Genetic Landscape of Renal Complications in Type 1 Diabetes.J Am Soc Nephrol. 2017 Feb;28(2):557-574. doi: 10.1681/ASN.2016020231. Epub 2016 Sep 19.
266 Rotigotine suppresses sleep-related muscle activity augmented by injection of dialysis patients' sera in a mouse model of restless legs syndrome.Sci Rep. 2019 Nov 8;9(1):16344. doi: 10.1038/s41598-019-52735-z.
267 Genome-wide association scan for survival on dialysis in African-Americans with type 2 diabetes.Am J Nephrol. 2011;33(6):502-9. doi: 10.1159/000327985. Epub 2011 May 5.
268 Sex-specific and pleiotropic effects underlying kidney function identified from GWAS meta-analysis.Nat Commun. 2019 Apr 23;10(1):1847. doi: 10.1038/s41467-019-09861-z.
269 A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.Endocrine. 2018 Jun;60(3):395-406. doi: 10.1007/s12020-018-1592-6. Epub 2018 Apr 9.
270 Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease.BMC Nephrol. 2018 Aug 2;19(1):192. doi: 10.1186/s12882-018-0986-2.
271 Targeting kidney inflammation as a new therapy for primary hyperoxaluria?.Nephrol Dial Transplant. 2019 Jun 1;34(6):908-914. doi: 10.1093/ndt/gfy239.
272 Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function.Nat Commun. 2016 Jan 21;7:10023. doi: 10.1038/ncomms10023.
273 Could the interaction between LMX1B and PAX2 influence the severity of renal symptoms?.Eur J Hum Genet. 2018 Nov;26(11):1708-1712. doi: 10.1038/s41431-018-0213-4. Epub 2018 Jul 4.
274 An inducible mouse model of podocin-mutation-related nephrotic syndrome.PLoS One. 2017 Oct 19;12(10):e0186574. doi: 10.1371/journal.pone.0186574. eCollection 2017.
275 Evolution of lung and kidney allograft function in patients receiving kidney after lung transplantation.Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13169. Epub 2017 Dec 21.
276 Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome Sequencing.Sci Rep. 2019 Nov 18;9(1):16952. doi: 10.1038/s41598-019-52474-1.
277 Genetic loci associated with renal function measures and chronic kidney disease in children: the Pediatric Investigation for Genetic Factors Linked with Renal Progression Consortium.Nephrol Dial Transplant. 2016 Feb;31(2):262-9. doi: 10.1093/ndt/gfv342. Epub 2015 Sep 28.
278 Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality.Mediators Inflamm. 2019 Jun 16;2019:3295725. doi: 10.1155/2019/3295725. eCollection 2019.
279 Cause-specific mortality in the general population with transient dipstick-proteinuria.PLoS One. 2019 Oct 2;14(10):e0223005. doi: 10.1371/journal.pone.0223005. eCollection 2019.